Skip to main content

Advertisement

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

Fig. 2

Evaluation of non-inferiority of test-adalimumab to reference adalimumab in terms of the proportion of patients who met good and moderate disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) European League Against Rheumatism (EULAR) response in the per-protocol (PP) population at 12 weeks, 95% CI for the difference −0.009 to 0.16 (a); the intention-to-treat (ITT) population at 12 weeks, 95% CI for the difference −0.02 to 0.17 (b); the PP population at 24 weeks, 95% CI for the difference −0.04 to 0.04 (c); and the ITT population at 24 weeks, 95% CI for the difference −0.09 to 0.09 (d)

Back to article page